Literature DB >> 26407924

Maintaining Control of Chronic Obstructive Airway Disease: Adherence to Inhaled Therapy and Risks and Benefits of Switching Devices.

Andrea S Melani1, Davide Paleari2.   

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are major obstructive airway diseases that involve underlying airway inflammation. The most widely used pharmacotherapies for asthma and COPD are inhaled agents that have been shown to be effective and safe in these patients. However, despite the availability of effective pharmacologic treatment and comprehensive treatment guidelines, the prevalence of inadequately controlled asthma and COPD is high. A main reason for this is poor adherence. Adherence is a big problem for all chronic diseases, but in asthma and COPD patients there are some additional difficulties because of poor inhalation technique and inhaler choice. Easier-to-use devices and educational strategies on proper inhaler use from health caregivers can improve inhaler technique. The type of device used and the concordance between patient and physician in the choice of inhaler can also improve adherence and are as important as the drug. Adherence to inhaled therapy is absolutely necessary for optimizing patient control. If disease control is not adequate despite good adherence, switching to a more appropriate inhaled therapy is recommended. By contrast, uninformed switching or switching to less user-friendly inhaler may impact disease control negatively. This critical review of the available literature is aimed to provide a guidance protocol on when a switch may be recommended in individual patients.

Entities:  

Keywords:  adherence; asthma; chronic obstructive pulmonary disease; disease control; ease of use; switching therapy

Mesh:

Substances:

Year:  2015        PMID: 26407924     DOI: 10.3109/15412555.2015.1045972

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  10 in total

1.  Influence of inhaler technique on asthma and COPD control: a multicenter experience.

Authors:  Aleksandra Dudvarski Ilic; Vladimir Zugic; Biljana Zvezdin; Ivan Kopitovic; Ivan Cekerevac; Vojislav Cupurdija; Nela Perhoc; Vesna Veljkovic; Aleksandra Barac
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-06

2.  Do not do in COPD: consensus statement on overuse.

Authors:  Felipe Villar-Álvarez; Raúl Moreno-Zabaleta; Jose Joaquin Mira-Solves; Eduardo Calvo-Corbella; Salvador Díaz-Lobato; Fernando González-Torralba; Ascensión Hernando-Sanz; Sara Núñez-Palomo; Sergio Salgado-Aranda; Beatriz Simón-Rodríguez; Paz Vaquero-Lozano; Isabel María Navarro-Soler
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-02

3.  The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol.

Authors:  Luca Richeldi; Alessio Piraino; Francesco Macagno; Gianluigi Micarelli; Eleonora Ingrassia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-01-27

Review 4.  How to Choose the Right Inhaler Using a Patient-Centric Approach?

Authors:  Didier Cataldo; Shane Hanon; Rudi V Peché; Daniel J Schuermans; Jean M Degryse; Isabelle A De Wulf; Karin Elinck; Mathias H Leys; Peter L Rummens; Eric Derom
Journal:  Adv Ther       Date:  2022-01-26       Impact factor: 3.845

Review 5.  Asthma phenotypes: the intriguing selective intervention with Montelukast.

Authors:  Cottini Marcello; Lombardi Carlo
Journal:  Asthma Res Pract       Date:  2016-08-12

Review 6.  Status of and strategies for improving adherence to COPD treatment.

Authors:  José Luis López-Campos; Esther Quintana Gallego; Laura Carrasco Hernández
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-10

7.  Comparison of correct technique and preference for Spiromax®, Easyhaler® and Turbuhaler®: a single-site, single-visit, crossover study in inhaler-naïve adult volunteers.

Authors:  Per Rönmark; Birgitta Jagorstrand; Guilherme Safioti; Sreedevi Menon; Leif Bjermer
Journal:  Eur Clin Respir J       Date:  2018-10-22

8.  Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution.

Authors:  Fulvio Braido; Angelo G Corsico; Davide Paleari; Alessio Piraino; Luca Cavalieri; Nicola Scichilone
Journal:  Ther Adv Respir Dis       Date:  2022 Jan-Dec       Impact factor: 4.031

Review 9.  Mapping of Modifiable Factors with Interdisciplinary Chronic Obstructive Pulmonary Disease (COPD) Guidelines Adherence to the Theoretical Domains Framework: A Systematic Review.

Authors:  Hancy Issac; Clint Moloney; Melissa Taylor; Jackie Lea
Journal:  J Multidiscip Healthc       Date:  2022-01-10

10.  A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler® in routine clinical practice.

Authors:  Ines Vinge; Jörgen Syk; Athanasios Xanthopoulos; Hendrik Laßmann; Mikko Vahteristo; Ulla Sairanen; Satu Lähelmä; Rudolf Hennig; Matthias Müller
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.